Medical Science
| Open Access |
DOI: Thalassemia. Etiology, Pathogenesis, Clinical Picture, Diagnosis, Treatment
Norbibi Yadgarova , Tashkent State Medical University, UzbekistanAbstract
Thalassemias are a group of inherited hemoglobinopathies caused by a quantitative deficiency in the synthesis of α- or β-globin chains of hemoglobin, leading to chronic hemolytic anemia of varying severity.
Keywords
Ineffective erythropoiesis, iron overload, hemoglobinopathies
References
Cappellini M.D., Porter J.B., Taher A.T., Viprakasit V. Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT). 4th ed. Nicosia: Thalassaemia International Federation; 2021.
Vos T., Lim S.S., Abbafati C., et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;401(10380):121–159.
Taher A.T., Musallam K.M., Cappellini M.D. β-Thalassemias. N Engl J Med. 2021;384(8):727–743.
Porter J.B., Garbowski M.W. Consequences and management of iron overload in β-thalassemia. Hematology Am Soc Hematol Educ Program. 2019;2019(1):337–345.
Pennell D.J., Udelson J.E., Arai A.E., et al. Cardiovascular function and treatment in β-thalassemia major: A consensus statement. Circulation. 2013;128(3):281–308.
FDA. Zynteglo (betibeglogene autotemcel) – Biologics License Application Approval Letter. U.S. Food and Drug Administration; 2022.
FDA. Mitapivat (Aqvesme) – Approval for treatment of anemia in thalassemia. U.S. Food and Drug Administration; 2026.
Galanello R., Origa R. Beta-thalassemia. Orphanet J Rare Dis. 2010;5:11.
Weatherall D.J., Clegg J.B. The Thalassaemia Syndromes. 4th ed. Oxford: Blackwell Science; 2001.
Taher A.T., Saliba A.N. Iron overload in thalassemia: different organs at different rates. Hematology. 2017;2017(1):265–271.
Download and View Statistics
Copyright License
Copyright (c) 2026 Norbibi Yadgarova
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.